Suppr超能文献

具有良好药代动力学特性且在体外和体内均具有过氧化物酶体增殖物激活受体激动剂活性的大型二聚体配体。

Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.

作者信息

Sauerberg Per, Bury Paul S, Mogensen John P, Deussen Heinz-Josef, Pettersson Ingrid, Fleckner Jan, Nehlin Jan, Frederiksen Klaus S, Albrektsen Tatjana, Din Nanni, Svensson L Anders, Ynddal Lars, Wulff Erik M, Jeppesen Lone

机构信息

Per Sauerberg, Novo Nordisk A/S, Novo Nordisk Park, 2760 Måløv, Denmark.

出版信息

J Med Chem. 2003 Nov 6;46(23):4883-94. doi: 10.1021/jm0309046.

Abstract

Two potent nonselective, but PPARalpha-preferring, PPAR agonists 5 and 6 were designed and synthesized in high yields. The concept of dimeric ligands in transcription factors was investigated by synthesizing and testing the corresponding dimers 7, 8a, and 8b in PPAR transactivation assays. The three dimeric ligands all showed agonist activity on all three PPAR receptor subtypes, but with different profiles compared to the monomers 5 and 6. Despite breaking all the "rule of five" criteria, the dimers had excellent oral bioavailability and pharmacokinetic properties, resulting in good in vivo efficacy in db/db mice. X-ray crystal structure and modeling experiments suggested that the dimers interacted with the AF-2 helix as well as with amino acid residues in the lipophilic pocket close to the receptor surface.

摘要

设计并高产合成了两种强效的非选择性但更倾向于PPARα的PPAR激动剂5和6。通过在PPAR反式激活试验中合成并测试相应的二聚体7、8a和8b,研究了转录因子中二聚体配体的概念。这三种二聚体配体在所有三种PPAR受体亚型上均表现出激动剂活性,但与单体5和6相比具有不同的特征。尽管违背了所有“五规则”标准,但这些二聚体具有优异的口服生物利用度和药代动力学性质,在db/db小鼠中产生了良好的体内疗效。X射线晶体结构和建模实验表明,这些二聚体与AF-2螺旋以及受体表面附近亲脂性口袋中的氨基酸残基相互作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验